XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage
clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company’s Annual General
and Special Meeting (the "Meeting"), which is scheduled to be held on September 12, 2024.
The Board of Directors of XORTX recommends that Shareholders
vote FOR ALL proposed items
At the Meeting, shareholders will be asked vote on the following agenda items for the ensuing year:
- fix the number of directors at seven;
- elect the board of directors;
- appoint the auditor; and
- approve the Company’s amended Stock Option Plan.
Additionally, leading independent proxy advisory firm Institutional Shareholder Services Inc. (ISS) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Meeting.
Your vote is important no matter how many shares you hold. Vote today.
The proxy voting deadline is 10:00 am (Calgary time) on Tuesday, September 10, 2024.
Meeting Details
XORTX will hold the Meeting on September 12, 2024, at 10:00 am (Calgary Time) at the offices of the Company at 3710 – 33rd Street NW, Calgary.
Please visit the Company’s website complete details and links to all relevant documents ahead of the Meeting at the link below:
https://www.xortx.com/investors/news-events/ir-calendar/detail/7671/an ....
Questions & Voting
If you have questions about the meeting matters or require voting assistance please contact XORTX‘s proxy solicitation agent, Laurel Hill Advisory Group at:
North American Toll Free: 1-877-452-7184 (1-416-304-0211 outside North America)
Email: assistance@laurelhill.com
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.